filings.toolsItem 6. SELECTED FINANCIAL DATA
4K characters. Original on sec.gov ·
Item 6. SELECTED FINANCIAL DATA
| Year Ended/As of December 31,(a) | ||||||||||||||||||||||||||||||||
| (MILLIONS, EXCEPT PER COMMON SHARE DATA) | 2020 | 2019 | 2018 | 2017 | 2016 | |||||||||||||||||||||||||||
| Revenues | $ | 41,908 | $ | 41,172 | $ | 40,825 | $ | 38,757 | $ | 38,664 | ||||||||||||||||||||||
| Income/(loss) from continuing operations | 7,021 | 10,867 | 3,861 | 13,558 | (67) | |||||||||||||||||||||||||||
| Total assets | 154,229 | 167,594 | 159,588 | 172,064 | 171,912 | |||||||||||||||||||||||||||
| Long-term obligations(b) | 64,835 | 66,844 | 63,972 | 69,981 | 80,957 | |||||||||||||||||||||||||||
| Earnings/(loss) per common share—basic(c) | ||||||||||||||||||||||||||||||||
| Income/(loss) from continuing operations attributable to Pfizer Inc. common shareholders | $ | 1.26 | $ | 1.95 | $ | 0.65 | $ | 2.26 | $ | (0.02) | ||||||||||||||||||||||
| Income from discontinued operations––net of tax(a) | 0.47 | 0.98 | 1.25 | 1.31 | 1.20 | |||||||||||||||||||||||||||
| Net income attributable to Pfizer Inc. common shareholders | $ | 1.73 | $ | 2.92 | $ | 1.90 | $ | 3.57 | $ | 1.18 | ||||||||||||||||||||||
| Earnings/(loss) per common share—diluted(c) | ||||||||||||||||||||||||||||||||
| Income/(loss) from continuing operations attributable to Pfizer Inc. common shareholders | $ | 1.24 | $ | 1.91 | $ | 0.64 | $ | 2.23 | $ | (0.02) | ||||||||||||||||||||||
| Income from discontinued operations––net of tax(a) | 0.47 | 0.96 | 1.23 | 1.29 | 1.19 | |||||||||||||||||||||||||||
| Net income attributable to Pfizer Inc. common shareholders | $ | 1.71 | $ | 2.87 | $ | 1.87 | $ | 3.52 | $ | 1.17 | ||||||||||||||||||||||
| Cash dividends declared per common share | $ | 1.53 | $ | 1.46 | $ | 1.38 | $ | 1.30 | $ | 1.22 |
(a)Amounts reflect the Upjohn Business and the Mylan-Japan collaboration as discontinued operations in all periods presented following the November 16, 2020 spin-off and combination of the Upjohn Business with Mylan and the December 21, 2020 termination of the Mylan-Japan collaboration. Income from discontinued operations––net of tax, including per common basic and diluted share amounts, for the year ended December 31, 2020 include the operating results of the Upjohn Business through November 16, 2020, the date of the spin-off and combination with Mylan. See Notes 1A and 2B. In addition, other acquisitions and business development activities completed in 2020, 2019 and 2018, including the acquisitions of Array and Therachon, and the contribution of our Consumer Healthcare business to the Consumer Healthcare JV, impacted financial results in the periods presented. See Note 1A. 2017 reflects the acquisition of AstraZeneca’s small molecule anti-infectives business and the sale of Hospira Infusion Systems net assets. 2016 reflects the acquisitions of Medivation and Anacor.
(b)Defined as Long-term debt, Pension benefit obligations, Postretirement benefit obligations, Noncurrent deferred tax liabilities, Other taxes payable and Other noncurrent liabilities.
(c)All years presented, except for 2016, reflect the impact of the TCJA on the Provision/(benefit) for taxes on income. For additional information see Note 5A.
Previous: Item 5. MARKET FOR THE COMPANY’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES · Next: Item 7. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS